MEDSIR connects oncology researchers worldwide with funding sources to design and execute investigator-initiated clinical trials. The company operates a lean tech stack (Excel, CDISC, Microsoft Office, cloud storage on Azure/AWS) focused on trial logistics rather than proprietary software—a pattern typical of services-driven research orgs. Hiring velocity is accelerating across research, ops, and finance roles, while pain points cluster around patient recruitment, cost control, and regulatory compliance, suggesting operational scaling pressure as trial volume grows.
MEDSIR is a private research services company founded in 2012 and headquartered in Barcelona. The company designs and manages clinical trials in oncology, acting as a broker between academic oncologists and pharmaceutical/biotech sponsors seeking to fund investigator-initiated research. MEDSIR supports over 200 active trial concepts spanning prostate, lung, breast, ovarian, and endometrial cancers. The company operates across the European Union and US, managing the full trial lifecycle from protocol development and site selection through patient recruitment to final publication. Revenue sources include trial sponsorship fees, vendor management, and public funding projects (H2020, European grants).
MEDSIR's core stack is Excel, CDISC (Clinical Data Interchange Standards Consortium), PowerPoint, Microsoft Office, Azure, and AWS. The tooling reflects a services-led model focused on trial management and data standardization rather than custom software development.
MEDSIR supports over 200 active trial ideas involving innovative oncology drugs across multiple cancer types, including prostate, lung, breast, ovarian, and endometrial cancer research.
Other companies in the same industry, closest in size